Promiscuous aggregate-based inhibitors promote enzyme unfolding

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 2067-2075

  Coan, Kristin E D ^a,b   Maltby, David A ^a,b   Burlingame, Alma L ^a   Shoichet, Brian K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mass Spectrometry Facility   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BETA LACTAMASE; BETA LACTAMASE AMPC; PEPSIN A; ROTTLERIN; SOLVENT; TRYPSIN;

ARTICLE; CONTROLLED STUDY; DENATURATION; DEUTERIUM HYDROGEN EXCHANGE; GEL ELECTROPHORESIS; MASS SPECTROMETRY; PROTEIN DEGRADATION; PROTEIN FOLDING;

ACETOPHENONES; BACTERIAL PROTEINS; BENZOPYRANS; BETA-LACTAMASES; CHROMATOGRAPHY, LIQUID; DEUTERIUM; ENZYME INHIBITORS; PEPTIDES; PROTEIN FOLDING; SOLVENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; WATER;

EID: 64549152003     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801605r     Document Type: Article

References (39)

1. Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 2005, 1, 146-148.
2. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and highthroughput screening. J. Med. Chem. 2002, 45, 1712-22.
3. Davies, S.; Reddy, H.; Caviano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
4. Frenkel, Y. V.; Clark, A. D. J.; Das, K.; Wang, Y.-H.; Lewi, P. J.; Janssen, P. A. J.; Arnold, E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem. 2005, 48, 1974-1983.
5. Lingameneni, R.; Vysotskaya, T.; Duch, D.; Hemmings, H. Inhibition of voltage-dependent sodium channels by Ro 31-8220, a "specific" protein kinase inhibitor. FEBS Lett. 2000, 473, 265-268.
6. Liu, H.; Wang, Z.; Regni, C.; Zou, X.; Tipton, P. A. Detailed kinetic studies of an aggregating inhibitor. Inhibition of phosphomannomutase/ phosphoglucomutase by Disperse Blue 56. Biochemistry 2004, 27, 8662-8669.
7. McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: not just for kinases anymore. J. Med. Chem. 2003, 46, 1478-1483.
8. Reddie, K.; Roberts, D.; Dore, T. Inhibition of kinesin motor proteins by adociasulfate-2. J. Med. Chem. 2006, 49, 4857-4860.
9. Seidler, J.; McGovern, S. L.; Doman, T.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 2003, 46, 4477-4486.
10. Turk, B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug DiscoVery 2006, 5, 785-799.
11. Feng, B. Y.; Shoichet, B. K. Small-molecule aggregates inhibit amyloid polymerization. Nat. Chem. Biol. 2008, 4, 197-199.
12. DeWitte, R. S. Avoiding physiochemical artifacts in early ADMETox experiments. Drug DiscoVery Today 2006, 11, 855-859.
13. Hann, M. M.; Oprea, T. I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 2004, 8, 255-263.
14. Keseru, G.; Makara, G. Hit discovery and hit-to-lead approaches. Drug DiscoVery Today 2006, 11, 741-748.
15. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
16. Rishton, G. M. Nonleadlikeness and leadlikeness in biochemical screening. Drug DiscoVery Today 2003, 8, 86-96.
17. Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E. M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjogren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; Vvon Der Saal, W.; Zimmermann, G.; Schneider, G. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. J. Med. Chem. 2002, 45, 137- 142.
18. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615- 2623.
19. Walters, W. P.; Ajay Murcko, M. A. Recognizing molecules with druglike properties. Curr. Opin. Chem. Biol. 1999, 3, 384-387.
20. Giannetti, A. M.; Koch, B. D.; Browner, M. F. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J. Med. Chem. 2008, 51, 574-580.
21. Feng, B.; Simeonov, A.; Jadhav, A.; Babaoglu, K.; Inglese, J.; Shoichet, B.; Austin, C. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 2007, 50, 2385- 2390.
22. McGovern, S. L.; Helfand, B. T.; Feng, B. Y.; Shoichet, B. K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 2003, 46, 4265-4272.
23. Ryan, A. J.; Gray, N. M.; Lowe, P. N.; Chung, C. W. Effect of detergent on "promiscuous" inhibitors. J. Med. Chem. 2003, 3448, 3451.
24. Smith, D.; Deng, Y.; Zhang, Z. Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry. J. Mass Spectrom. 1997, 32, 135-146.
25. Zhang, Z.; Smith, D. L. Determination of amide hydrogen exchange by mass spectrometry: a new tool for protein structure elucidation. Protein Sci. 1993, 2, 522-531.
26. Englander, S. W.; Sosnick, T. R.; Englander, J. J.; Mayne, L. Mechanisms and uses of hydrogen exchange. Curr. Opin. Chem. Biol. 1996, 6, 18-23.
27. Mandell, J. M.; Falick, A. M.; Komives, E. A. Identification of protein-protein interfaces by decreased amide proton solvent accessibility. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 14705-14710.
28. Hoofnagle, A. N.; Resing, K. A.; Goldsmith, E. J.; Ahn, N. G. Changes in protein conformational mobility upon activation of extracellular regulated protein kinase-2 as detected by hydrogen exchange. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 956-961.
29. Yan, X.; Watson, J.; Ho, P. S.; Deinzer, M. L. Mass spectrometric approaches using electrospray ionization charge states and hydrogendeuterium exchange for determining protein structures and their conformational changes. Mol. Cell. Proteomics 2004, 3, 10-23.
30. Wales, T. E.; Engen, J. R. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 2006, 25, 158- 170.
31. Burlingame, A. L.; Boyd, R. K.; Gaskell, S. J. Mass Spectrometry. Anal. Chem. 1996, 68, 634R-683R.
32. Mandell, J. M.; Falick, A. M.; Komives, E. A. Measurement of amide hydrogen exchange by MALDI-TOF mass spectrometry. Anal. Chem. 1998, 70, 3987-3995.
33. Coan, K. E. D.; Shoichet, B. K. Stability and equilibria of promiscuous aggregates in high protein milieus. Mol. BioSyst. 2007, 3, 208-213.
34. Shoichet, B. K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 2006, 49, 7274-7277.
35. Coan, K. E. D.; Shoichet, B. K. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J. Am. Chem. Soc. 2008, 130, 9606-9612.
36. Alkaabi, K. M.; Yafea, A.; Ashraf, S. S. Effect of pH on thermaland chemical-induced denaturation of GFP. Appl. Biochem. Biotechnol. 2005, 126, 149-156.
37. Weston, G. S.; Blazquez, J.; Baquero, F.; Shoichet, B. K. Structurebased enhancement of boronic acid-based inhibitors of AmpC betalactamase. J. Med. Chem. 1998, 41, 4577-4586.
38. Fraczkiewicz, R.; Braun, W. Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. J. Comput. Chem. 1998, 19, 319-333.
39. Powers, R. A.; Caselli, E.; Focia, P. J.; Prati, F.; Shoichet, B. K. Structures of ceftazidine and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design. Biochemistry 2001, 40, 9207-9214.